Meeting
2012 ASCO Annual Meeting
Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).
Authors
Marc Peeters
Antwerp University Hospital, Edegem, Belgium
Marc Peeters , Jean-Yves Douillard , Eric Van Cutsem , Salvatore Siena , Kathy Zhang , Richard Thomas Williams , Jeffrey S. Wiezorek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3581)
DOI
10.1200/jco.2012.30.15_suppl.3581
Abstract #
3581
Poster Bd #
32B
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
First Author: Cathy Eng
Poster
2014 ASCO Annual Meeting
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
First Author: Ace Joseph Hatch
Poster
2014 Gastrointestinal Cancers Symposium
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
First Author: Ace J. Hatch
Poster
2011 ASCO Annual Meeting
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
First Author: K. Oliner